Abbott Laboratories (ABT) Accumulated Expenses (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Accumulated Expenses data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 3.86% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 3.86% YoY), and the FY2025 full-year result was $1.7 billion, up 2.59% from the prior year.
• Accumulated Expenses slipped to $1.2 billion in Q1 2026, from $1.7 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q1 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses dropped 4.27% in 2023 and grew 11.59% in 2025, its largest moves.
• Tracing ABT's Accumulated Expenses over 5 years: stood at $1.6 billion in 2022, then gained by 2.63% to $1.6 billion in 2023, then grew by 6.51% to $1.7 billion in 2024, then grew by 2.59% to $1.7 billion in 2025, then slumped by 30.54% to $1.2 billion in 2026.
• Business Quant data shows ABT's Accumulated Expenses at $1.2 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.7 billion in Q3 2025.